1 Øjenklinikken, HovedOrtoCentret Rigshospitalet, Rigshospitalet, The Capital Region of Denmark2 unknown
Ipilimumab is a monoclonal antibody targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) that allows increased survival and, occasionally, complete remission, in the treatment of metastatic melanoma. The most frequent adverse effects are attributed to dysimmunity. We report the case of a female patient who developed orbital myositis during treatment with ipilimumab.
Annales De Dermatologie Et De Venereologie, 2013, Vol 140, Issue 6-7, p. 448-51